NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) on a method to use a chewing gum composition comprising cannabinoids and nicotine according to the patented formula to treat or alleviate tobacco smoking. The USPTO granted this allowance from AXIM’s patent application 15/494,514 filed on April 23, 2017.
Under this patent allowance, AXIM plans to formulate a chewing gum that contains cannabidiol (CBD) and nicotine to aid smoking cessation utilizing the Company’s proprietary delivery mechanism. Other cannabinoids are also covered under the invention in this patent allowance.
“At the end of the day, our main goal is to help as many people in need as we can. There are over one billion tobacco smokers around the world, and it is estimated that 70% of U.S. smokers want to quit,” said AXIM® Biotech CEO John W. Huemoeller II. “With this patent, we look to provide a unique and effective solution for those who want to quit smoking.”
It is well known that smoking cigarettes poses many health risks. Research has shown that smoking causes a rise in blood pressure due to an increase in cardiac output and total peripheral vascular resistance. Alternatively, research also suggests that CBD can assist in lowering blood pressure in healthy subjects.
Due to the massive number of smokers and large percentage that would like to quit smoking, the smoking cessation market is expected to be worth $21.8 billion by 2024. This presents a huge opportunity for companies like AXIM that are looking to provide the market with unique options.
To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of plant and laboratory-derived cannabinoid and oncological therapeutics. AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions, such as the intense side effects of chemotherapy, through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.
Currently, Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. Learn more here. For more information, please visit www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM® Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact:
Chief Executive Officer CMW Media
Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246
Industrieweg 40, Unit B4
3401 MA IJsselstein
Investor Relations Contact: